Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating tumor DNA and liquid biopsy in oncology.
Cescon DW, Bratman SV, Chan SM, Siu LL. Cescon DW, et al. Nat Cancer. 2020 Mar;1(3):276-290. doi: 10.1038/s43018-020-0043-5. Epub 2020 Mar 20. Nat Cancer. 2020. PMID: 35122035 Review.
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).
Chiu JW, Hotte SJ, Kollmannsberger CK, Renouf DJ, Cescon DW, Hedley D, Chow S, Moscow J, Chen Z, Perry M, Diaz-Padilla I, Tan D, Hirte H, McWhirter E, Chen H, Siu LL, Bedard PL. Chiu JW, et al. Among authors: cescon dw. Invest New Drugs. 2016 Feb;34(1):104-11. doi: 10.1007/s10637-015-0313-8. Epub 2015 Dec 19. Invest New Drugs. 2016. PMID: 26686201 Free PMC article. Clinical Trial.
Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
Pezo RC, Chen TW, Berman HK, Mulligan AM, Razak AA, Siu LL, Cescon DW, Amir E, Elser C, Warr DG, Sridhar SS, Yu C, Wang L, Stockley TL, Kamel-Reid S, Bedard PL. Pezo RC, et al. Among authors: cescon dw. Breast Cancer Res Treat. 2018 Feb;168(1):159-168. doi: 10.1007/s10549-017-4580-2. Epub 2017 Nov 24. Breast Cancer Res Treat. 2018. PMID: 29177603 Free PMC article.
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL. Clouthier DL, et al. J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0. J Immunother Cancer. 2019. PMID: 30867072 Free PMC article. Clinical Trial.
MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex.
Ku A, Chan C, Aghevlian S, Cai Z, Cescon D, Bratman SV, Ailles L, Hedley DW, Reilly RM. Ku A, et al. Among authors: cescon d. Mol Pharm. 2019 Aug 5;16(8):3559-3568. doi: 10.1021/acs.molpharmaceut.9b00422. Epub 2019 Jul 11. Mol Pharm. 2019. PMID: 31242384
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
Dowling RJO, Sparano JA, Goodwin PJ, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Thorat MA, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Whelan TJ, Wolff AC, Woodgett JR, Kalinsky K, Hayes DF. Dowling RJO, et al. Among authors: cescon dw. JNCI Cancer Spectr. 2019 Aug 10;3(4):pkz049. doi: 10.1093/jncics/pkz049. eCollection 2019 Dec. JNCI Cancer Spectr. 2019. PMID: 32337478 Free PMC article.
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
Dowling RJO, Kalinsky K, Hayes DF, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Thorat MA, Whelan TJ, Wolff AC, Woodgett JR, Sparano JA, Goodwin PJ. Dowling RJO, et al. Among authors: cescon dw. JNCI Cancer Spectr. 2019 Aug 10;3(4):pkz050. doi: 10.1093/jncics/pkz050. eCollection 2019 Dec. JNCI Cancer Spectr. 2019. PMID: 32337479 Free PMC article.
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors.
Taylor K, Loo Yau H, Chakravarthy A, Wang B, Shen SY, Ettayebi I, Ishak CA, Bedard PL, Abdul Razak A, R Hansen A, Spreafico A, Cescon D, Butler MO, Oza AM, Lheureux S, Stjepanovic N, Van As B, Boross-Harmer S, Wang L, Pugh TJ, Ohashi PS, Siu LL, De Carvalho DD. Taylor K, et al. J Immunother Cancer. 2020 Aug;8(2):e000883. doi: 10.1136/jitc-2020-000883. J Immunother Cancer. 2020. PMID: 32753546 Free PMC article. Clinical Trial.
134 results